Serina Therapeutics Inc（SER）股票分析SERSerina Therapeutics Inc

Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Serina Therapeutics Inc is currently trading at $2.46, which is significantly below the analyst price target of $8, indicating potential upside. However, the stock has a low RSI of 35.955, suggesting it is oversold, but the recent 5-day change of -14.29% raises concerns about short-term volatility. The company has also reported substantial net losses, with a net income of -$8.93 million in Q2 2026, which is a significant risk. Therefore, while there is potential for long-term growth, the current financial instability and insider selling (up 489.78%) suggest caution for new investors.